Skip to content

Rare Diseases: Initial Public Offering (IPO) Bussiness Developments

September 16, 2013

This Blog Post presents business development news for Initial Public Offerings (IPOs) in the rare disease space.

According to the Renaissance Capital IPO Center, as of September 8, 2013, the following is a snapshot of the IPO market:

•   131 IPOs in 2013, raising a total of $28.5 billion & producing an average return of 30%
•   54 IPOs in past 90 days, with total proceeds of $11.3 billion & an average return of 22%.

I – Acceleron Pharma

At the beginning of August 2013, Acceleron Pharma, a Cambridge, Massachusetts biopharmaceutical company developing protein therapeutics for cancer and rare diseases, announces the filing of a registration statement on Form S-1, with the U.S. Securities and Exchange Commission (SEC), relating to the proposed initial public offering of its common stock.

Acceleron is partnered with Celgene for 2 mid-stage rare blood disorder programs :

•   Orphan drug ACE-536 for Beta-Thalassemia
•   Orphan drug ACE-536 for & Myelodysplastic Syndromes (MDS).

Acceleron Pharma’s IPO is planned for the upcoming week of 09/15/13, for 4.7 million shares, priced at $13 – $15. The IPO is expected to be priced Wednesday evening (09/18/13) and trade Thursday (09/19/13) morning on the NASDAQ global market. The IPO is managed by Citigroup and Leerink Swann. “XLRN” is the proposed NASDAQ symbol.

II – Epizyme

Epizyme, another Cambridge biopharmaceutical company, is developing personalized therapeutics for genetically defined cancers. The company recently completes a successful IPO in June 2013. Epizyme within the last month receives :

•   A FDA Orphan Drug Designation in August 2013 for EPZ-5676, a small molecule DOT1L inhibitor designed to treat acute leukemias in which the MLL gene is rearranged due to a chromosomal translocation (MLL-r)

•   A U.S. Patent in September 2013 for EPZ-5676.

III – Fate Therapeutics

Fate Therapeutics is a San Diego-based biopharmaceutical company focusing on adult stem cell modulators for hematologic malignancies and rare diseases, such as Lysosomal Storage Disorders (LSDs) and Muscular Dystrophies (MDs). Fate Therapeutics announces in August 2013, the filing of a registration statement on Form S-1, with the U.S. SEC, identifying a plan to raise as much as $69 million. The company plans on being listed on the NASDAQ under the ticker symbol “FATE”.

Please Note “Team_room” By HJ van Ree (Own work) [CC-BY-SA-3.0] |Wikimedia Commons.

Copyright © 2012-2013, Orphan Druganaut Blog. All rights reserved.

Advertisements
One Comment

Trackbacks & Pingbacks

  1. Rare Diseases: Initial Public Offering (IPO) Bu...

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: